Vanguard Group Inc. Sells 38,287 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Vanguard Group Inc. decreased its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 0.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,848,923 shares of the company's stock after selling 38,287 shares during the period. Vanguard Group Inc. owned about 5.80% of Day One Biopharmaceuticals worth $74,106,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently modified their holdings of the company. Franklin Resources Inc. boosted its stake in Day One Biopharmaceuticals by 2.3% in the third quarter. Franklin Resources Inc. now owns 3,869,632 shares of the company's stock valued at $55,336,000 after buying an additional 87,262 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Day One Biopharmaceuticals by 10.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,432,697 shares of the company's stock valued at $19,961,000 after purchasing an additional 136,458 shares during the last quarter. Wellington Management Group LLP increased its position in Day One Biopharmaceuticals by 142.1% during the 3rd quarter. Wellington Management Group LLP now owns 721,581 shares of the company's stock worth $10,052,000 after purchasing an additional 423,543 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Day One Biopharmaceuticals by 5.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 535,501 shares of the company's stock valued at $6,785,000 after purchasing an additional 28,053 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Day One Biopharmaceuticals by 43.4% in the fourth quarter. Bank of New York Mellon Corp now owns 244,829 shares of the company's stock valued at $3,102,000 after buying an additional 74,091 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company's stock.

Remove Ads

Day One Biopharmaceuticals Stock Performance

Shares of DAWN stock traded down $0.13 during mid-day trading on Tuesday, hitting $7.09. The company's stock had a trading volume of 466,351 shares, compared to its average volume of 1,116,578. The company has a market cap of $718.61 million, a PE ratio of -6.88 and a beta of -1.24. The company's fifty day simple moving average is $9.23 and its 200-day simple moving average is $11.98. Day One Biopharmaceuticals, Inc. has a 52 week low of $6.41 and a 52 week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.34). The business had revenue of $29.21 million for the quarter, compared to analyst estimates of $27.11 million. On average, equities analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

Analysts Set New Price Targets

DAWN has been the subject of a number of research reports. JPMorgan Chase & Co. dropped their price target on Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a research note on Wednesday, March 5th. Bank of America dropped their target price on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, April 3rd. Needham & Company LLC reissued a "buy" rating and issued a $32.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group decreased their price objective on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a report on Tuesday, March 25th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $32.29.

Insider Activity

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the transaction, the chief executive officer now owns 128,015 shares in the company, valued at approximately $1,531,059.40. The trade was a 8.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Charles N. York II sold 4,370 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $52,265.20. Following the completion of the sale, the chief financial officer now directly owns 252,638 shares of the company's stock, valued at $3,021,550.48. The trade was a 1.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,064 shares of company stock worth $251,925 over the last three months. 8.40% of the stock is currently owned by insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.